These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 20127562)
1. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. Rizzo M IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Samaha FF; McKenney J; Bloedon LT; Sasiela WJ; Rader DJ Nat Clin Pract Cardiovasc Med; 2008 Aug; 5(8):497-505. PubMed ID: 18506154 [TBL] [Abstract][Full Text] [Related]
4. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Davis KA; Miyares MA Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. Cuchel M; Bloedon LT; Szapary PO; Kolansky DM; Wolfe ML; Sarkis A; Millar JS; Ikewaki K; Siegelman ES; Gregg RE; Rader DJ N Engl J Med; 2007 Jan; 356(2):148-56. PubMed ID: 17215532 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lomitapide in Hypercholesterolemia. Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870 [TBL] [Abstract][Full Text] [Related]
7. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related]
8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
9. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Perry CM Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215 [TBL] [Abstract][Full Text] [Related]
10. Microsomal transfer protein inhibition in humans. Cuchel M; Rader DJ Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709 [TBL] [Abstract][Full Text] [Related]
11. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578 [TBL] [Abstract][Full Text] [Related]
12. Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors. Goldberg AC J Clin Lipidol; 2013; 7(3 Suppl):S16-20. PubMed ID: 23642324 [TBL] [Abstract][Full Text] [Related]
13. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]
14. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage. Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698 [TBL] [Abstract][Full Text] [Related]
15. Lomitapide for the treatment of hypercholesterolemia. Berberich AJ; Hegele RA Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687 [TBL] [Abstract][Full Text] [Related]
16. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
17. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
18. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia. Sirtori CR; Pavanello C; Bertolini S Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866 [TBL] [Abstract][Full Text] [Related]
19. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880 [TBL] [Abstract][Full Text] [Related]
20. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]